<SEC-DOCUMENT>0001178913-25-002871.txt : 20250813
<SEC-HEADER>0001178913-25-002871.hdr.sgml : 20250813
<ACCEPTANCE-DATETIME>20250813170353
ACCESSION NUMBER:		0001178913-25-002871
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20250813
FILED AS OF DATE:		20250813
DATE AS OF CHANGE:		20250813

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IM Cannabis Corp.
		CENTRAL INDEX KEY:			0001792030
		STANDARD INDUSTRIAL CLASSIFICATION:	MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40065
		FILM NUMBER:		251212711

	BUSINESS ADDRESS:	
		STREET 1:		KIBBUTZ GLIL YAM
		CITY:			CENTRAL DISTRICT
		STATE:			L3
		ZIP:			4690500
		BUSINESS PHONE:		416-256-4202

	MAIL ADDRESS:	
		STREET 1:		KIBBUTZ GLIL YAM
		CITY:			CENTRAL DISTRICT
		STATE:			L3
		ZIP:			4690500
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>zk2533630.htm
<DESCRIPTION>6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: ZKG
         Document created using Broadridge PROfile 25.5.1.5318
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div>
      <div style="text-align: center; line-height: 1.25;"><font style="font-weight: bold;"> <br>
        </font></div>
      <div style="text-align: center; line-height: 1.25;"><font style="font-weight: bold; font-size: 14pt;">UNITED STATES</font><br>
        <font style="font-size: 14pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</font><br>
        Washington, D.C. 20549<br>
        <br>
        <font style="font-size: 14pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Form 6-K</font><br style="line-height: 1.25;">
        <br>
        <font style="font-weight: bold;">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16</font><br>
        <font style="font-weight: bold;">UNDER THE SECURITIES EXCHANGE ACT OF 1934</font></div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: center; line-height: 1.25;">For the month of <font style="font-weight: bold;"><u>August 2025 (Report No. 3)</u></font>.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: center; line-height: 1.25;">Commission File Number: <font style="font-weight: bold;"><u>001-40065</u></font></div>
      <div style="text-align: center; line-height: 1.25;"><br>
        <font style="font-size: 16pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;"><u>IM Cannabis Corp.</u></font><br>
        (Exact Name of Registrant as Specified in Charter)<br style="line-height: 1.25;">
        <br>
        <font style="font-weight: bold;"><u>Kibbutz Glil Yam, Central District, Israel 4690500</u></font><br>
        (Address of principal executive offices)</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25;">Form 20-F <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9746;</font>&#160;&#160;&#160;&#160;&#160; Form 40-F <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div><br>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">CONTENTS</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Amendment to Common Share Purchase Warrants</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">On August 13, 2025, IM Cannabis Corp. (the &#8220;<font style="font-weight: bold;">Company</font>&#8221;) entered into agreements with the holders of certain common share purchase warrants (the &#8220;<font style="font-weight: bold;">Warrants</font>&#8221;) originally issued by the Company as part of its private placement offering that closed on November 12, 2024 (the &#8220;<font style="font-weight: bold;">2024 Private Placement</font>&#8221;). The Warrants were
        exercisable immediately upon issuance at an exercise price of C$4.32 per common share and had a termination date of November 12, 2026.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">Pursuant to the August 13, 2025 amendments (the &#8220;<font style="font-weight: bold;">Amendments</font>&#8221;), the Company reduced the exercise price of each Warrant from C$4.32 per common share to C$3.43
        per common share and extended the expiration date of each Warrant from November 12, 2026 to July 31, 2030. Except as set forth above, all other terms of the Warrants remain unchanged and in full force and effect.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">The foregoing descriptions of the Warrants and the Amendments contained herein do not purport to be complete and are qualified in their entirety by reference to the Form of Warrant and the Form of
        Amendment, which are attached as Exhibits 99.1 and 99.2, respectively, to this Report of Foreign Private Issuer on Form 6-K and are incorporated herein by reference.</div>
      <div style="line-height: 1.25;">&#160;&#160;&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Press Release</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">On August 13, 2025, the Company issued a press release titled: &#8220;IM Cannabis Announces Warrant Amendments <u>and Form F-3 Resale Registration Statement Filing</u>&#8221;. A copy of this press release is
        furnished herewith as Exhibit 99.3.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Incorporation by Reference</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">This Report of Foreign Private Issuer on Form 6-K is incorporated by reference into the Company&#8217;s Registration Statements on Form F-3 (File No. <a href="https://www.sec.gov/Archives/edgar/data/1792030/000117891325002247/zk2533384.htm">333-288346</a> and <a href="https://www.sec.gov/Archives/edgar/data/1792030/000117891325002865/zk2533632.htm">333-289571</a>) filed with the Securities and
        Exchange Commission to be a part thereof from the date on which this Report of Foreign Private Issuer on Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">EXHIBIT INDEX</div>
      <div style="line-height: 1.25;">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z4438828b920340c7941f8cb41f59815c">

          <tr>
            <td style="width: 10%; vertical-align: middle;">
              <div style="line-height: 1.25; font-weight: bold;">Exhibit No.</div>
            </td>
            <td style="width: 90%; vertical-align: middle;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 10%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><a href="https://www.sec.gov/Archives/edgar/data/1792030/000117891325002865/exhibit_4-4.htm">99.1</a></div>
            </td>
            <td style="width: 90%; vertical-align: middle;">
              <div style="line-height: 1.25; font-family: 'Times New Roman';"><a href="https://www.sec.gov/Archives/edgar/data/1792030/000117891325002865/exhibit_4-4.htm">Form of Common Warrant (incorporated herein by reference to Exhibit 4.4 to the
                  Company&#8217;s Registration Statement on Form F-3 (File No. 333-289571) filed with the SEC on August 13, 2025)</a></div>
            </td>
          </tr>
          <tr>
            <td style="width: 10%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><a href="https://www.sec.gov/Archives/edgar/data/1792030/000117891325002865/exhibit_4-5.htm">99.2</a></div>
            </td>
            <td style="width: 90%; vertical-align: middle;">
              <div style="line-height: 1.25; font-family: 'Times New Roman';"><a href="https://www.sec.gov/Archives/edgar/data/1792030/000117891325002865/exhibit_4-5.htm">Form of Amendment to Common Warrant (incorporated herein by reference to Exhibit 4.5
                  to Company&#8217;s Registration Statement on Form F-3 (File No. 333-289571) filed with the SEC on August 13, 2025)</a></div>
            </td>
          </tr>
          <tr>
            <td style="width: 10%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><a href="exhibit_99-3.htm">99.3</a></div>
            </td>
            <td style="width: 90%; vertical-align: middle;">
              <div style="line-height: 1.25;"><a href="exhibit_99-3.htm">Press Release, dated August 13, 2025, titled &#8220;IM Cannabis Announces Warrant Amendments&#8221;</a></div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">SIGNATURE</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
        authorized.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z944f8e5f1c6743929ae3b1a8ffe4ebf0">

          <tr>
            <td style="width: 50%; vertical-align: middle;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td colspan="2" style="vertical-align: middle;">
              <div style="line-height: 1.25; font-weight: bold;">IM CANNABIS CORP.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: middle;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td colspan="2" style="vertical-align: middle;">
              <div style="line-height: 1.25;">(Registrant)</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: middle;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 5%; vertical-align: middle;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 44.72%; vertical-align: middle;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: middle;">
              <div style="line-height: 1.25;">Date: August 13, 2025</div>
            </td>
            <td style="width: 5%; vertical-align: middle;">
              <div style="line-height: 1.25;">By:</div>
            </td>
            <td style="width: 44.72%; vertical-align: middle; border-bottom: #000000 2px solid;">
              <div style="line-height: 1.25;">/s/ Oren Shuster</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: middle;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 5%; vertical-align: middle;">
              <div style="line-height: 1.25;">Name:&#160;&#160;&#160;</div>
            </td>
            <td style="width: 44.72%; vertical-align: middle;">
              <div style="line-height: 1.25;">Oren Shuster</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: middle;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 5%; vertical-align: middle;">
              <div style="line-height: 1.25;">Title:</div>
            </td>
            <td style="width: 44.72%; vertical-align: middle;">
              <div style="line-height: 1.25;">Chief Executive Officer and Director</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>2
<FILENAME>exhibit_99-3.htm
<DESCRIPTION>EXHIBIT 99.3
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: ZKG
         Document created using Broadridge PROfile 25.5.1.5318
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div style="text-align: right;"><u><font style="font-weight: bold;">Exhibit 99.3</font></u><br>
    </div>
    <div> <br>
    </div>
    <div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold;">IM Cannabis Announces Warrant Amendments and Form F-3 Resale Registration Statement Filing</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;"><font style="font-weight: bold;">Toronto, Ontario and Glil Yam, Israel &#8211; August 13, 2025</font> &#8211; IM Cannabis Corp. (&#8220;<font style="font-weight: bold;">IM Cannabis</font>&#8221; or the &#8220;<font style="font-weight: bold;">Company</font>&#8221;) (NASDAQ: IMCC), a leading medical cannabis company with operations in Israel and Germany, announces that it has agreed with holders (each, a &#8220;<font style="font-weight: bold;">Holder</font>&#8221;) of common
        share purchase warrants (&#8220;<font style="font-weight: bold;">November 2024<u style="border-bottom: 1px solid;">&#160;</u>Warrants</font>&#8221;) issued by the Company as part of its non-brokered private placement offering which closed on November 12, 2024 to:
        (x) reduce the exercise price of each November 2024 Warrant from C$4.32 to C$3.43; and (y) extend the expiration date of each November 2024 Warrant from November 12, 2026 to July 31, 2030 (together, the &#8220;<font style="font-weight: bold;">Transaction</font>&#8221;).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Form F-3 Resale Registration Statement</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">The Company also announces that, further to its press release dated July 31, 2025 (the &#8220;<font style="font-weight: bold;">July 31 Release</font>&#8221;), it has filed a resale registration statement on
        Form F-3 (the &#8220;<font style="font-weight: bold;">Resale Registration Statement</font>&#8221;) with the Securities and Exchange Commission (the &#8220;<font style="font-weight: bold;">SEC</font>&#8221;). Capitalized terms not otherwise defined herein have the meanings
        attributed to them in the July 31 Release.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25">
        <div style="line-height: 1.25;">
          <div style="text-align: justify; line-height: 1.25;">The Resale Registration Statement registered an aggregate of 4,982,517 Common Shares comprised of (i) 1,202,000 Common Shares,
            (ii) 848,000 Common Shares issuable upon exercise of the Pre-Funded Warrants, (iii) 2,050,000 Common Shares issuable upon the exercise of the Warrants, (iv)
            140,000 Common Shares issuable upon the exercise of certain Common Share purchase warrants issued to Pure Equity Ltd. (&#8220;<font style="font-weight: bold;">Finder&#8217;s Warrants</font>&#8221;)
            in connection with the Offering, and (v) 742,517 Common Shares issuable upon the exercise of the November 2024 Warrants (including, in each case, any securities issued or issuable as a result of stock splits, stock dividends, combinations,
            recapitalizations or similar events or pursuant to anti-dilution or other adjustments). A copy of the Resale Registration Statement will be available on the Company&#8217;s issuer profile on SEDAR+ at www.sedarplus.ca&#160;and Edgar at www.sec.gov/edgar.</div>
        </div>
      </div>
      <div style="line-height: 1.25"> <br>
      </div>
      <div style="text-align: justify; line-height: 1.25;">The Resale Registration Statement has been filed with the SEC but has not yet become effective. The Common Shares and Common Shares issuable upon the exercise of the Pre-Funded Warrants, the
        Warrants, the Finder&#8217;s Warrants and the November 2024 Warrants, as applicable, covered by the Resale Registration Statement (the &#8220;Securities&#8221;) may not be sold, nor may offers to buy any such Securities be accepted, prior to the time the Resale
        Registration Statement becomes effective by the SEC. If declared effective by the SEC, the selling shareholders may use the prospectus relating to the Resale Registration Statement from time to time to resell their Securities. The Company will not
        receive any proceeds from the sale of any of the Securities by the selling shareholders.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">This news release does not constitute an offer to sell&#160; or the solicitation of an offer to buy any of the Company&#8217;s securities, including the Securities, nor shall there be any sale of these
        securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Related Party Transaction</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">Oren Shuster, a director and officer of the Company, Shmulik Arbel, a director of the Company and Rafael Gabay, an insider of the Company, (together, the &#8220;<font style="font-weight: bold;">Participating
          Insiders</font>&#8221;) each participated in the Transaction as a Holder of November 2024 Warrants. Mr. Shuster holds 194,110 November 2024 Warrants, Mr. Arbel holds 48,349 November 2024 Warrants and Mr. Gabay holds 194,088 November 2024 Warrants.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">The participation of the Participating Insiders in the Transaction constitutes a &#8220;related party transaction&#8221;, as such term is defined in Multilateral Instrument 61-101 &#8211; <font style="font-style: italic;">Protection of Minority Security Holders in Special Transactions</font> (&#8220;<font style="font-weight: bold;">MI 61-101</font>&#8221;) and would have required the Company to receive minority shareholder approval for and obtain a formal valuation
        for the subject matter of, the Transaction in accordance with MI 61-101, prior to the completion of the Transaction. However, in completing the Transaction, the Company has relied on exemptions from the formal valuation and minority shareholder
        approval requirements of MI 61-101 contained in sections 5.5(a) and 5.7(1)(a) of MI 61-101 in respect of the Participating Insiders&#8217; participation in the Transaction as neither the fair market value (as determined under MI 61-101) of the subject
        matter of, nor the fair market value of the consideration for, the Transaction, insofar as it involved the Participating Insiders, exceeded 25% of the Company&#8217;s market capitalization (as determined under MI 61-101).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25;">The Transaction was approved by the members of the board of directors of the Company (the &#8220;<font style="font-weight: bold;">Board</font>&#8221;) who are independent for the purposes of the Transaction
        insofar as it involved the Participating Insiders. No special committee was established in connection with the Transaction.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">Further details will be included in a material change report to be filed by the Company. The Company did not file a material change report more than 21 days before the closing date of the
        Transaction as the Participating Insiders were treated equally with each of the other Holders. In the Company&#8217;s view, the shorter period was necessary to permit the Company to close the Transaction in a timeframe consistent with usual market
        practice for transactions of this nature and was reasonable in the circumstances.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Early Warning Disclosure</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">This press release is being issued in accordance with the requirements of National Instrument 62-104 &#8211; <font style="font-style: italic;">Take-Over Bids and Issuer Bids</font> and National
        Instrument 62-103 &#8211; <font style="font-style: italic;">The Early Warning System and Related Take-Over Bid and Insider Reporting Issues</font>, in connection with the Early Warning Reports (as defined herein) which will be filed by Oren Shuster,
        whose registered address is&#160;22, Hanachal St. Ra&#8217;anana, Israel, 4356990 and Rafael Gabay, whose registered address is Shmerling 8, Tel Aviv, Israel 5251241 (collectively, the &#8220;<font style="font-weight: bold;">Acquirors</font>&#8221;) in connection with
        their acquisition of securities of the Company, whose registered address is Kibbutz Glil Yam, Central District, Israel, 4690500.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">Effective August 13, 2025, the Company completed the Transaction.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">Immediately prior to the completion of the Transaction, Oren Shuster, along with his joint actor, Ewave Group Ltd., a privately held entity of which Mr. Shuster owns and controls 50% of the
        outstanding voting, owned an aggregate of 898,350 Common Shares, 194,110 Common Share purchase warrants exercisable into Common Shares, 21,875 options exercisable into Common Shares and a debenture in the principal amount C$260,935.40, convertible
        into up to 99,975 Common Shares at a deemed price of C$2.61 per Common Share, which represented approximately 17.12% of the Company&#8217;s issued and outstanding Common Shares on a non-diluted basis (based on 5,246,812 Common Shares issued and
        outstanding prior to the completion of the Transaction), and 21.83% on a partially diluted basis if Mr. Shuster converted all of the convertible securities owned or controlled by him.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">As a result of the Transaction, Mr. Shuster, along with its joint actor, Ewave Group Ltd., a privately held entity of which Mr. Shuster owns and controls 50% of the outstanding voting, now
        beneficially owns or controls an aggregate of 898,350 Common Shares, 194,110 Common Share purchase warrants exercisable into Common Shares, 21,875 options exercisable into Common Shares and a debenture in the principal amount C$260,935.40,
        convertible into up to 99,975 Common Shares at a deemed price of C$2.61 per Common Share, which represents approximately 17.12% of the Company&#8217;s issued and outstanding Common Shares on a non-diluted basis (based on 5,246,812 Common Shares issued
        and outstanding as of the date hereof), and 21.83% on a partially diluted basis if Mr. Shuster converted all of the convertible securities owned or controlled by him.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">Immediately prior to the completion of the Transaction, Rafael Gabay, along with his joint actor, Ewave Group Ltd., a privately held entity of which Mr. Gabay owns and controls 50% of the
        outstanding voting, owned an aggregate of 518,525 Common Shares, 244,637 Common Share purchase warrants exercisable into Common Shares, 1,500 options exercisable into Common Shares and a debenture in the principal amount C$260,278.70, convertible
        into up to 99,723 Common Shares at a deemed price of C$2.61 per Common Share, which represented approximately 9.88% of the Company&#8217;s issued and outstanding Common Shares on a non-diluted basis (based on 5,246,812 Common Shares issued and
        outstanding prior to the completion of the Transaction), and 15.48% on a partially diluted basis if Mr. Gabay converted all of the convertible securities owned or controlled by him.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25;">As a result of the Transaction, Mr. Gabay, along with its joint actor, Ewave Group Ltd., a privately held entity of which Mr. Gabay owns and controls 50% of the outstanding voting, now beneficially
        owns or controls an aggregate of 518,525 Common Shares, 244,637 Common Share purchase warrants exercisable into Common Shares, 1,500 options exercisable into Common Shares and a debenture in the principal amount C$260,278.70, convertible into up to
        99,723 Common Shares at a deemed price of C$2.61 per Common Share, which represents approximately 9.88% of the Company&#8217;s issued and outstanding Common Shares on a non-diluted basis (based on 5,246,812 Common Shares issued and outstanding as of the
        date hereof), and 15.48% on a partially diluted basis if Mr. Gabay converted all of the convertible securities owned or controlled by him.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">The Acquirors acquired the above-noted securities for investment purposes. In the future, the Acquirors will evaluate their respective investment in the Company from time to time and may, based on
        such evaluation, market conditions and other circumstances, increase or decrease their respective shareholdings as circumstances require through market transactions, private agreements, or otherwise.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">The Acquirors currently have no plans or intentions which would result in a corporate transaction, a sale or transfer of a material amount of the assets of the Company or any of its subsidiaries, a
        change in the board of directors or management of the Company, including any plans or intentions to change the number or term of directors or to fill any existing vacancies on the board, a material change in the Company&#8217;s business or corporate
        structure, a change in the Company&#8217;s charter, bylaws or similar instruments or another action which might impede the acquisition of control of Company by any person or company, a class of securities of the Company being delisted from, or ceasing to
        be authorized to be quoted on, a marketplace, the Company ceasing to be a reporting issuer in any jurisdiction of Canada, a solicitation of proxies from securityholders, or an action similar to any of those enumerated.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">The Acquiror most recently filed early warning reports on November 12, 2024 (the &#8220;<font style="font-weight: bold;">Prior EWRs</font>&#8221;). Since then, the Company has issued Common Shares in a variety
        of transactions, which has resulted in the Acquirors&#8217;, together with their joint actors&#8217;, holdings to decrease by more than 2%. As there was a material change to the Prior EWRs, the requirement to file an early warning report under applicable
        Canadian Securities legislation was triggered (together, the &#8220;<font style="font-weight: bold;">Early Warning Reports</font>&#8221;).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">Copies of the Early Warning Reports may be found at SEDAR+<font style="font-style: italic;">&#160;</font>at<font style="font-style: italic;">&#160;</font>www.sedarplus.ca under IM Cannabis&#8217; profile. For
        further information, or to obtain copies of the Early Warning Reports, please contact the Acquirors by emailing michal.l@imcannabis.com or calling 972 542815033.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">About IM Cannabis Corp.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">IM Cannabis (Nasdaq: IMCC) is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets. The
        Company leverages a transnational ecosystem powered by a unique data-driven approach and a globally sourced product supply chain. With an unwavering commitment to responsible growth and compliance with the strictest regulatory environments, the
        Company strives to amplify its commercial and brand power to become a global high-quality cannabis player.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">The IM Cannabis ecosystem operates in Israel through its subsidiaries, which imports and distributes cannabis to medical patients, leveraging years of proprietary data and patient insights. The
        Company also operates medical cannabis retail pharmacies, online platforms, distribution center, and logistical hubs in Israel that enable the safe delivery and quality control of IM Cannabis products throughout the entire value chain. In Germany,
        the IM Cannabis ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Company Contact:</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">Anna Taranko, Director Investor &amp; Public Relations</div>
      <div style="text-align: justify; line-height: 1.25;">IM Cannabis Corp.</div>
      <div style="text-align: justify; line-height: 1.25;">+49 157 80554338</div>
      <div style="text-align: justify; line-height: 1.25;">a.taranko@imcannabis.de</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">Oren Shuster, Chief Executive Officer</div>
      <div style="text-align: justify; line-height: 1.25;">IM Cannabis Corp.</div>
      <div style="text-align: justify; line-height: 1.25;">+972-77-3603504</div>
      <div style="text-align: justify; line-height: 1.25;">info@imcannabis.com</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Cautionary Note Regarding Forward-Looking Information</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">This press release contains forward-looking information or forward-looking statements under applicable Canadian and United States securities laws (collectively, &#8220;<font style="font-weight: bold;">forward-looking
          statements</font>&#8221;). All information that addresses activities or developments that we expect to occur in the future are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as
        &#8220;seek&#8221;, &#8220;anticipate&#8221;, &#8220;believe&#8221;, &#8220;plan&#8221;, &#8220;estimate&#8221;, &#8220;expect&#8221;, &#8220;likely&#8221; and &#8220;intend&#8221; and statements that an event or result &#8220;may&#8221;, &#8220;will&#8221;, &#8220;should&#8221;, &#8220;could&#8221; or &#8220;might&#8221; occur or be achieved and other similar expressions. Forward-looking statements
        are based on the estimates and opinions of management on the date the statements are made. In the press release, such forward-looking statements include, but are not limited to, statements relating to the Resale Registration Statement becoming
        effective and selling shareholders reselling their Securities pursuant to the Resale Registration Statement</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">Forward-looking statements are based on assumptions that may prove to be incorrect, including but not limited to: the Company&#8217;s ability to focus and resources to achieve sustainable and profitable
        growth in its highest value markets; the Company&#8217;s ability to mitigate the impact of the Israel-Hamas war on the Company; the Company&#8217;s ability to take advantage of the legalization of medicinal cannabis in Germany; the Company&#8217;s ability to carry
        out its stated goals, scope, and nature of operations in Germany, Israel, and other jurisdictions the Company may operate. The above lists of forward-looking statements and assumptions are not exhaustive. Since forward-looking statements address
        future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated or implied by such forward looking statements due to a number of factors and
        risks. These include: the failure of the Company to comply with applicable regulatory requirements in a highly regulated industry; unexpected changes in governmental policies and regulations in the jurisdictions in which the Company operates; the
        Company&#8217;s ability to continue to meet the listing requirements of the NASDAQ Capital Market; any unexpected failure to maintain in good standing or renew its licenses; the ability of the Company and its subsidiaries (collectively, the &#8220;<font style="font-weight: bold;">Group</font>&#8221;) to deliver on their sales commitments or growth objectives; the reliance of the Group on third-party supply agreements to provide sufficient quantities of medical cannabis to fulfil the Group&#8217;s
        obligations; the Group&#8217;s possible exposure to liability, the perceived level of risk related thereto, and the anticipated results of any litigation or other similar disputes or legal proceedings involving the Group; the impact of increasing
        competition; any lack of merger and acquisition opportunities; adverse market conditions; the inherent uncertainty of production quantities, qualities and cost estimates and the potential for unexpected costs and expenses; risks of product
        liability and other safety-related liability from the usage of the Group&#8217;s cannabis products; supply chain constraints; reliance on key personnel; the risk of defaulting on existing debt; risks surrounding war, conflict and civil unrest in Eastern
        Europe and the Middle East, including the impact of the Israel-Hamas war on the Company, its operations and the medical cannabis industry in Israel; risks associated with the Company focusing on the Israel and Germany markets; the inability of the
        Company to achieve sustainable profitability and/or increase shareholder value; the inability of the Company to actively manage costs and/or improve margins; the inability of the company to grow and/or maintain sales; the inability of the Company
        to meet its goals and/or strategic plans; the inability of the Company to reduce costs and/or maintain revenues; the Company&#8217;s inability to take advantage of the legalization of medicinal cannabis in Germany. Please see the other risks,
        uncertainties and factors set out under the heading &#8220;Risk Factors&#8221; in the Company&#8217;s annual report dated March 31, 2025, which is available on the Company&#8217;s issuer profile on SEDAR+ at www.sedarplus.cawww.sedarplus.ca and Edgar at
        www.sec.gov/edgarwww.sec.gov/edgar. Any forward-looking statement included in this press release is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward
        looking information is made. The Company does not undertake any obligation to update forward-looking statements except as required by applicable securities laws. Investors should not place undue reliance on forward-looking statements. Forward
        looking statements contained in this press release are expressly qualified by this cautionary statement.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25">
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
